| Code | CSB-RA023996MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to PRA-052, targeting TNFSF8 (tumor necrosis factor superfamily member 8), also known as CD30 ligand or CD153. TNFSF8 is a type II transmembrane glycoprotein primarily expressed on activated T cells, macrophages, and certain dendritic cells. It binds to CD30 (TNFRSF8) and plays critical roles in immune regulation, including T cell activation, cytokine production, and inflammatory responses. TNFSF8/CD30 interactions are particularly significant in the pathogenesis of lymphoproliferative disorders, Hodgkin lymphoma, and anaplastic large cell lymphoma, where aberrant CD30 signaling contributes to malignant transformation and disease progression. This pathway is also implicated in autoimmune conditions and transplant rejection.
As a biosimilar to the reference antibody PRA-052, this product provides researchers with a reliable tool for investigating TNFSF8 biology, CD30-CD30L signaling mechanisms, and their roles in immune-mediated diseases and hematologic malignancies. It supports studies exploring therapeutic targeting strategies and biomarker development in oncology and immunology research.
There are currently no reviews for this product.